

AWARD CLOSEOUT GUIDANCE  
Grants and Cooperative Agreements Supported by  
National Institute for Occupational Safety and Health  
Centers for Disease Control and Prevention  
September 8, 2005

CDC/NIOSH will close out a grant as soon as possible after expiration of a grant that will not be extended or after termination of a grant as provided in 45 CFR 74.71 to 74.73. Grantees are required to submit the Closeout Report comprised of the three Final Reports described below within 90 days of the project end date. This date is on the notice of grant award, and can also be obtained from recipient organization's business office. Failure to submit timely and accurate final reports may affect future funding to the organization or awards for the same Principal Investigator (PI). If the final reports cannot be submitted within 90 days, please submit a written request and justification for an extension of the expiration date at least 10 days prior to the expiration date (per the PHS Grants Policy Statement). Otherwise, there is no guarantee that the extension request can be processed in time and a letter of reprimand may be sent to the institution. The request must be sent to the Grants Management Officer identified under Contacts, and the PI should follow-up to verify that the request has been received.

In order to facilitate the preparation of these Final Reports by the PI and Business Office, NIOSH and CDC Procurement and Grants Office (PGO) have prepared these instructions. However, these instructions do not replace or supercede any Health and Human Services or CDC policy.

The required Final Reports are:

- A. Final Progress Report
- B. Final Financial Status Report
- C. Final Invention Statement

The Final Reports must be sent to the Grants Management Officer. A paper original, two (2) copies, and an electronic copy are requested. For information on where to send the Final Reports and who to contact for additional information, see "Contacts" provided at the end of this document.

**A. Final Progress Report:**

The Final Progress Report represents the **most important** report a PI prepares for a grant and it should provide a synthesis of the overall results from the project. This final report communicates the results of the research, and NIOSH uses this report as a principal reporting tool to inform the Congress, Executive Branch, NIOSH Director, and other stakeholders on the success and impact of NIOSH extramural research programs in addressing occupational safety and health issues. Thus, NIOSH relies on the PI to provide a cogent and well-organized report of findings that can be understood by a broad audience.

Although there is no standard Final Progress Report format, to assist a PI in developing this report, NIOSH and CDC PGO have developed the following guidance.

**Title Page.** The title page should contain the PI's name, the institution and laboratory or department name, city, state, zip code, e-mail address, project title, date, number of report (if any), co-investigators, project director, sponsors, grant number and a list of the start date and end date (or anticipated end date).

**Table of Contents.**

**List of Abbreviations.**

**Abstract.** An overview of the project that is limited to no more than two pages (one page is preferred), which states the occupational safety and health issue that was addressed, the importance of the problem, approach, key findings, and how the results can be utilized in the workplace. This section may contain much of the same information as in the sections below, but it is intended to be a brief summary for informing others about the key findings and importance of the project. The abstract should be a stand alone document that is suitable for distribution to a wide audience and may be provided to members of Congress, the Secretary of Health and Human Services, the Director of NIOSH, and many others. NIOSH often uses this abstract without editing.

**Highlights/Significant Findings.** Significant findings are similar to conclusions. These are the important results of the project, and they should relate to the specific aims of the project. The most important findings should be listed first. Separate findings should be in different paragraphs.

**Translation of Findings.** This section provides an interpretation of how the significant findings of the project can be used in prevention of workplace diseases and injuries. If specific recommendations are made for reducing hazards on the job, the language should be as non-technical as possible in order to communicate to employers or employees. It is very important that a PI identify how these findings have been or may be adopted in the workplace. If the findings are such that they cannot yet be applied to the workplace, this section should address how these findings can be used to guide future activities.

**Outcomes/Relevance/Impact.** This section should be a concise statement of the outcomes, relevance, and/or impact of your project.

**Scientific Report.** The report should contain: background for the project, specific aims, procedures, methodology, results and discussion, and conclusions. More detail should be provided in this section than is included in the "Significant Findings" section. Each of the specific aims originally planned or added during the project should be addressed in terms of what was accomplished or why progress was not made, so that there will be a complete documentation of the efforts on the grant. **If there is any information that is considered as proprietary** information for commercial purposes, be sure to label it so that the government can evaluate the

request. Otherwise, the entire report may be released upon request under the Freedom of Information Act.

**Publications.** Any published or “in press” articles that have resulted from the grant support (such support from NIOSH should be acknowledged in the articles), should be listed and annotations should be provided that describe how the articles relate to the specific aims. Please do not submit manuscripts or other restricted information.

Three copies of all reprints are needed. In addition, investigators are encouraged to inform NIOSH of other publications resulting from this project as they are published after the final report is submitted.

### **Citation Format Examples**

#### Journal Article

Clark WW, Popelka GR: [1989] Hearing Levels of Railroad Trainmen. *Laryngoscope* 99:1151-1157

Gomes M, Santella RM: [1990] Immunologic Methods for the Detection of Benzo(a)pyrene Metabolites in Urine. *Chemical Research in Toxicology*, in press

#### Book

Trush MA, Thompson DC: [1989] Enhancement of Chemical Activation Via Radical-Dependent Mechanisms: An Emerging Concept in Chemical-Chemical Interactions. In: *Oxygen Radicals in Biology and Medicine*, (eds. MG Simic, KA Taylor, JF Ward, CV Sonntag), Plenum Publishing Corporation, pp 739B744

Murlas CG: [1989] Environmental Airway of Mucosal and Changes in Hyperreactivity. In *Airway Epithelium: Structure and Function in Health and Disease*, (eds. S Farmer, D Hay), Marcel Decker Inc., in press

#### Proceedings

Park MY, Casali JG: [1989] A Laboratory Simulation of Selected In-field Influences on Hearing Protector Performance. *Proc of 1989 Human Factors Society 33rd Annual Conference*, Denver, Colorado, 946-950, October 16-20

#### Dissertation/Thesis

Holton PM: [1986] Particle Size-Dependent leakage through the Face seal of Negative Pressure Half-Mask Respirators, Ph.D. Thesis, University of Cincinnati

**Inclusion of gender and minority study subjects.** Use the gender and minority inclusion table provided in the PHS-2590, if applicable.

**Inclusion of Children.** Where appropriate, indicate whether children were involved in the study or how the study was relevant for conditions affecting children (see "Public Policy Requirements and Objectives—Requirements for Inclusiveness in Research Design—Inclusion of Children as Subjects in Clinical Research" and the PHS-398).

**Materials available for other investigators.** Describe any data, research materials (such as cell lines, DNA probes, animal models), protocols, software, or other information resulting from the research that are available to be shared with other investigators and how it may be accessed.

## **B. Final Financial Status Report**

**Forms.** The institution's business office will determine which form (SF-269 or SF-269A) should be used for the Financial Status Report (FSR). Follow the instructions provided on the back of the form. Please provide an original and two (2) copies.

For those organizations receiving their funds through the Health and Human Services Payment Management System (PMS), final reports, as specified by PMS, must be submitted to that office. It is the responsibility of the grantee to reconcile reports submitted to PMS and to the CDC awarding office.

Long Form (SF-269) - (PDF)

Short Form (SF-269A) - (PDF)

**Requirement.** A final FSR is required for any grant that is expired, terminated, transferred to a new grantee, or modifications in the project requiring adjustment of funds. These include awards which will not be competitively extended through award of a new competitive segment.

### **Process.**

The final FSR must:

- Cover the period of time since the previous FSR submission or as much of the competitive segment as has been funded prior to termination.
- Have no unliquidated obligations. Unliquidated obligations on a cash basis are obligations incurred, but not yet paid. On an accrual basis, they are obligations incurred, but for which an outlay has not yet been recorded.
- Indicate the exact balance of unobligated funds. Unobligated funds must be returned to CDC/PGO or must be reflected by an appropriate accounting adjustment in accordance with instructions from the GMO or from the payment office.

Withdrawal of the unobligated balance following expiration or termination of a grant is not considered an adverse action and may not be appealed.

Where the submission of a revised final FSR results in additional claims by the grantee, CDC will consider the approval of such claims subject to the following minimum criteria:

- The charges must represent allowable costs under the provisions of the grant.
- There must have been an unobligated balance for the given budget period that is sufficient to cover the additional claim. Such a claim may be considered regardless of whether the unobligated balance was moved forward to offset the award for a subsequent budget period.
- Funds must be available from the applicable appropriation.
- CDC/PGO must receive the revised FSR within 15 months of its due date.

### **C. Final Invention Statement and Certification**

**Form.** Final Invention Statement (HHS Form 568 - Fillable) - (PDF)

**Process.** The grantee must submit a Final Invention Statement and Certification (HHS-568), whether or not an invention(s) results from work under the grant. The final invention statement/certification must be signed by the PI and the institution's authorized official. This document must list all inventions that were conceived or first actually reduced to practice during the course of work under the project, from the original effective date of support through the date of expiration or termination, whether or not previously reported. If there were no inventions, the statement should indicate "None".

### **CONTACTS FOR FINAL REPORTS**

Send hard copies of Final Reports to:

Final Report Office  
Attn MaryAnn P. Monroe  
Acquisition and Assistance Field Branch, PGO  
Centers for Disease Control and Prevention  
626 Cochrans Mill Road  
Pittsburgh, Pennsylvania 15236-0070  
Phone: 412-386-5075

Send electronic copies of Final Reports to: [MPMonroe@cdc.gov](mailto:MPMonroe@cdc.gov) and [EWard1@cdc.gov](mailto:EWard1@cdc.gov)

For questions, contact:

CDC/PGO – Larry Guess, e-mail [lguess@cdc.gov](mailto:lguess@cdc.gov), phone 412-386-6826

NIOSH – Ms. Erica Ward, e-mail: [EWard1@cdc.gov](mailto:EWard1@cdc.gov), phone 404-498-2523